Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?

Kalijn Bol • 31 May 2026
ASCO 2026
Melanoma Skin Cancer Checkpoint Inhibitors Cobimetinib Ipilimumab Nivolumab Vemurafenib

Kalijn Bol, MD, Radboud University Medical Center, Nijmegen, Netherlands, discusses whether induction BRAF/MEK inhibition has a place in the treatment regime for melanoma patients. Dr Bol highlights patients with brain metastases on dexamethasone who may require BRAF/MEK inhibition to reduce the tumor load prior to starting immunotherapy, and patients with rapid disease who also cannot start immunotherapy immediately. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kalijn Bol

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026
Melanoma at ASCO 2026: IGNYTE, OptimUM-02, and a Phase I/II trial of anzu-cel
0:58
Melanoma at ASCO 2026: IGNYTE, OptimUM-02, and a Phase I/II trial of anzu-cel
Allison Betof Warner • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals